Abhinav’s background includes greater than 20 years of experience in the areas of engineering, immunology and formulation development.
Abhinav is driven by two professional passions:


1.) Development of creative solutions for solving healthcare related problems
2.) Helping patients achieve the best quality of life that they desire

As the founder of ImmunoMetabolix, Abhinav aims to utilize the formulations developed to modulate the metabolism of immune system to resolve immune related disorders in patients. ImmunoMetabolix is a clinical-stage biotechnology company focused on applying a novel engineering approach to develop metabolically-fit immunotherapies for patients with cancer, autoimmune, and inflammatory diseases.


Abhinav Acharya is an Assistant Professor in the Department of Chemical Engineering at the Arizona State University. He earned his Master’s and Ph.D. in Materials Science and Engineering at the University of Florida, Gainesville and was a postdoctoral scholar at the University of California, Berkeley and University of Pittsburgh. He started as an assistant professor at Arizona State University in January 2019. Acharya's research expertise is in formulations, and immunology, with a particular emphasis on technology development. He is an active member of Society for Biomaterials, and Controlled Release Society.

Vladimir’s unique background includes over 20 years of experience in the areas of strategy, marketing, business growth, and optimizing the patient/customer experience. Vladimir is driven by two professional passions:


1.) Help patients by delivering better outcomes through novel yet simple patient-centric solutions
2.) Create high-impact businesses through out-of-the-box entrepreneurship

As the CEO of ImmunoMetabolix, Vladimir combines the two for an opportunity to provide extraordinary outcomes for patients, caregivers, providers, advocacy groups, payers, and overall stakeholders. ImmunoMetabolix is a clinical-stage biotechnology company focused on applying a novel engineering approach to develop metabolically-fit immunotherapies for patients with cancer, autoimmune, and inflammatory diseases.


Vladimir is also the Founder of Phase 4 Digital. Phase 4 is a certified minority-owned marketing consulting firm that provides niche expertise in the areas of brand, digital, and omni-channel marketing and marketing services for Life Science and Healthcare organizations. Phase 4 is focused on improving conversations between patients and their Health Care Providers for better outcomes.

Vladimir also serves as Partner, Strategic Advisor and Board Member for Asentech, a Digital Acceleration company focused on strategy, research and digital / technology development and execution within the Life Sciences. In 2020, Asentech, LLC acquired xReach.io, a technology company Vladimir co-founded which focused on Conversational AI and disruptive innovation for Life Sciences. Previously, Vladimir co-founded and served as the Chief Marketing Officer for The Encima Group (acquired by Indegene Inc.), a business analytics consulting company which was listed as one of the Inc. 5000 Fastest Growing Private Companies in America - for four years in a row.

Before Encima, Vladimir held various pharmaceutical brand marketing and leading-edge driving roles in his 12 years of experience at Bristol-Myers Squibb. He has won multiple marketing and innovation awards but he considers his greatest achievements to be launching YERVOY (ipilimumab), educating on a new approach (at that time) to fight cancer: immunotherapy and immuno-oncology, and giving patients a chance to live longer.
Vladimir has an MBA in Marketing and a BS in Industrial Engineering from Rutgers University.
Vladimir always enjoys fun times with his family and friends, volunteering in his community, reading, and working out.